p.95 抽出テキスト

714. The Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–1801. https://doi.org/10.1016/S0140-6736(22)02074-8 715. Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine 2021;41:101163. https://doi.org/10.1016/j.eclinm.2021.101163 716. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377: 2337–2348. https://doi.org/10.1056/NEJMoa1708337 717. Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 2016;17:127. https://doi. org/10.1186/s12882-016-0337-0 718. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383: 2219–2229. https://doi.org/10.1056/NEJMoa2025845 719. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385:2252–2263. https://doi.org/10.1056/NEJMoa2110956 720. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–484. https://doi.org/10. 1093/eurheartj/ehab777 721. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZ, Chertow GM, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant 2020;35: 1700–1711. https://doi.org/10.1093/ndt/gfaa234 722. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J 2020;41:2379–2392. https://doi.org/10.1093/eurheartj/ehaa183 723. Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR- Reduced. J Am College Cardiol 2021;77:1397–1407. https://doi.org/10.1016/j.jacc. 2021.01.044 724. Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. Heart Fail 2021;9:254–264. https://doi.org/10.1016/j.jchf. 2020.11.009 725. Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep 2022;7:36–45. https://doi.org/10. 1016/j.ekir.2021.10.008 726. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium–glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 2022;45: 2991–2998. https://doi.org/10.2337/dc22-0294 727. Weir MR, Slee A, Sun T, Balis D, Oh R, de Zeeuw D, et al. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clin Kidney J 2021;14:1396–1402. https://doi.org/10.1093/ckj/sfaa133 728. Seidu S, Kunutsor SK, Topsever P, Khunti K. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin–angiotensin–aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 2022;5:e00303. https://doi.org/10.1002/edm2.303 729. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol 2022;10:645–654. https://doi.org/10.1016/S2213-8587(22) 00172-3 730. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016;39:694–700. https://doi.org/10.2337/dc15-2322 731. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81–98. https://doi.org/10.2165/ 11534750-000000000-00000 732. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; 52:373–384. https://doi.org/10.1007/s40262-013-0046-9 733. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605–617. https://doi.org/10. 1016/S2213-8587(18)30104-9 734. ClinicalTrials.gov. FLOW: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). https:// clinicaltrials.gov/ct2/show/NCT03819153 (4 March 2023) 735. Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2022;2: CD008834. https://doi.org/10.1002/14651858.CD008834.pub4 736. Molnar AO, Bota SE, Garg AX, Harel Z, Lam N, McArthur E, et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol 2016;27:2825–2832. https://doi.org/10.1681/ ASN.2015050535 737. ClinicalTrials.gov. Aspirin to Target Arterial Events in Chronic Kidney Disease (ATTACK). https://clinicaltrials.gov/ct2/show/NCT03796156 (19 April 2022) 738. ClinicalTrials.gov. Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK). https://clinicaltrials.gov/ct2/show/ NCT03969953 (19 April 2022) 739. Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med 2020;382: 1608–1618. https://doi.org/10.1056/NEJMoa1915925 740. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382: 1395–1407. https://doi.org/10.1056/NEJMoa1915922 741. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482–2494. https://doi.org/10.1056/NEJMoa1205624 742. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382:1268–1277. https://doi.org/10.1016/S0140-6736(13)60897-1 743. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619–637. https://doi.org/10.1053/j.ajkd.2009.06.004 744. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, De Zeeuw D, Eckardt K-U, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032. https://doi.org/10.1056/NEJMoa0907845 745. George C, Echouffo-Tcheugui JB, Jaar BG, Okpechi IG, Kengne AP. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature. BMC Med 2022;20:1–12. https://doi.org/10.1186/s12916-022-02438-6 746. Spertus JA, Jones PG, Maron DJ, Mark DB, O’Brien SM, Fleg JL, et al. Health status after invasive or conservative care in coronary and advanced kidney disease. N Engl J Med 2020;382:1619–1628. https://doi.org/10.1056/NEJMoa1916374 747. Aboyans V, Ricco J-B, Bartelink M-L, Björck M, Brodmann M, Cohner T, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J 2017;39: 763–816. https://doi.org/10.1093/eurheartj/ehx095 748. Keller K, Schmitt VH, Vosseler M, Brochhausen C, Münzel T, Hobohm L, et al. Diabetes mellitus and its impact on patient-profile and in-hospital outcomes in peripheral artery disease. J Clin Med 2021;10:5033. https://doi.org/10.3390/jcm10215033 749. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329–1340. https://doi.org/10.1016/S0140-6736(13)61249-0 750. Malyar NM, Freisinger E, Meyborg M, Lüders F, Gebauer K, Reinecke H, et al. Amputations and mortality in in-hospital treated patients with peripheral artery disease and diabetic foot syndrome. J Diabetes Complications 2016;30:1117–1122. https://doi.org/10.1016/j.jdiacomp.2016.03.033 751. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333–3341. https://doi.org/10.2337/diacare.26.12.3333 752. Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367–2375. https://doi.org/10.1056/NEJMra1615439 753. Buso G, Aboyans V, Mazzolai L. Lower extremity artery disease in patients with type 2 diabetes. Eur J Prev Cardiol 2019;26(2_suppl):114–124. https://doi.org/10.1177/ 2047487319880044 754. Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, et al. Microvascular disease, peripheral artery disease, and amputation. Circulation 2019;140: 449–458. https://doi.org/10.1161/CIRCULATIONAHA.119.040672 755. Behroozian A, Beckman JA. Microvascular disease increases amputation in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 2020;40:534–540. https://doi.org/10.1161/ATVBAHA.119.312859 756. Walsh J, Hoffstad O, Sullivan M, Margolis D. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med 2016;33: 1493–1498. https://doi.org/10.1111/dme.13054 757. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S1–S109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006

ESC Guidelines                                                                                                                                                                                          4137

Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026